Pharmacoeconomic studies of bypassing agents in mild‐to‐moderate bleeding episodes in patients with hemophilia and inhibitors: a critical appraisal

Review article

Pharmacoeconomic studies of bypassing agents in mild‐to‐moderate bleeding episodes in patients with hemophilia and inhibitors: a critical appraisal

V Erich De Paula and C Margareth Ozelo
Affiliation: Hemocentro da UNICAMP, Campinas, Brazil

ABSTRACT

The development of neutralizing antibodies against factor VIII and IX complicates the clinical management of patients with hemophilia, and adds significant costs to their treatment. For this reason, several formal economic analysis have been performed comparing treatment of mild and moderate bleeding episodes in these patients in an effort to determine whether one of the two available bypassing agents would be cost‐effective compared with the other. Here we review and discuss the available evidence about the economic aspects of the alternatives for on‐demand treatment of mild and moderate bleeding episodes for hemophilia patients with inhibitors.

Keywords: Bleeds, hemophilia, inhibitor, economic, recombinant activated factor VII (rFVIIa), activated prothrombin complex concentrate (aPCC)
Correspondence: Margareth Castro Ozelo, Rua Carlos Chagas, 480, Distrito Barão Geraldo, PO. Box 6198, 13084‐878 Campinas, São Paulo, Brazil